Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-09-18

Clinical Trial Update: Black Widow Spider Antivenin for Patients With Systemic Latrodectism [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating a Black Widow spider antivenin for systemic latrodectism; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Black Widow Spider Antivenin

Snippet

Sponsor: Instituto Bioclon S.A. de C.V. | Conditions: Latrodectism | Phase 3 | Status: COMPLETED | Results posted: 2017-09-18